Literature DB >> 10362793

High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.

A van den Berg1, L Visser, S Poppema.   

Abstract

Hodgkin's lymphoma is characterized by the combination of Reed-Sternberg (R-S) cells and a prominent inflammatory cell infiltrate. One of the intriguing questions regarding this disease is what is causing the influx of T lymphocytes into the involved tissues. We applied the serial analysis of gene expression (SAGE) technique on the Hodgkin's lymphoma-derived cell line L428 and on an Epstein-Barr virus (EBV)-transformed lymphoblastoid B-cell line. A frequently expressed tag in L428 corresponded to the T-cell-directed CC chemokine TARC. Reverse transcription polymerase chain reaction analyses demonstrated expression of TARC in nodular sclerosis (NS) and mixed cellularity (MC) classical Hodgkin's lymphomas but not in NLP Hodgkin's lymphoma, anaplastic large-cell lymphomas, and large-B-cell lymphomas with CD30 positivity. Two of five cases of T-cell-rich B-cell lymphoma (TCRBCL) were TARC positive. RNA in situ hybridization (ISH) showed a strong signal for TARC in the cytoplasm of R-S cells, and immunohistochemical staining confirmed the presence of the TARC protein in the R-S cells of NS and MC Hodgkin's lymphomas. The lymphocytic and histiocytic (L&H)-type cells of nodular lymphocyte predominance Hodgkin's lymphoma and the neoplastic cells of non-Hodgkin's lymphomas with the exception of two cases of TCRBCL did not stain for TARC. TARC is known to bind to the CCR4 receptor, which is expressed on activated Th2 lymphocytes. The immunophenotype of lymphocytes surrounding R-S cells is indeed Th2-like, and by RNA ISH these lymphocytes showed a positive signal for the chemokine receptor CCR4. The findings suggest that production of TARC by the R-S cells may explain the characteristic T-cell infiltrate in classical Hodgkin's lymphoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362793      PMCID: PMC1876772          DOI: 10.1016/S0002-9440(10)65424-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  CCR5 is characteristic of Th1 lymphocytes.

Authors:  P Loetscher; M Uguccioni; L Bordoli; M Baggiolini; B Moser; C Chizzolini; J M Dayer
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

2.  Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB.

Authors:  K M Wood; M Roff; R T Hay
Journal:  Oncogene       Date:  1998-04-23       Impact factor: 9.867

3.  Nodular lymphocyte predominance type of Hodgkin's disease is a germinal center lymphoma.

Authors:  W Timens; L Visser; S Poppema
Journal:  Lab Invest       Date:  1986-04       Impact factor: 5.662

4.  The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease.

Authors:  S Poppema
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

5.  Serial analysis of gene expression.

Authors:  V E Velculescu; L Zhang; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

6.  A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene.

Authors:  P Fischer; E Nacheva; D Y Mason; P D Sherrington; C Hoyle; F G Hayhoe; A Karpas
Journal:  Blood       Date:  1988-07       Impact factor: 22.113

7.  Characteristics of Hodgkin's disease-derived cell lines.

Authors:  V Diehl; H H Kirchner; H Burrichter; H Stein; C Fonatsch; J Gerdes; M Schaadt; W Heit; B Uchanska-Ziegler; A Ziegler; F Heintz; K Sueno
Journal:  Cancer Treat Rep       Date:  1982-04

8.  Constitutive expression of various chemokine genes in human T-cell lines infected with human T-cell leukemia virus type 1: role of the viral transactivator Tax.

Authors:  M Baba; T Imai; T Yoshida; O Yoshie
Journal:  Int J Cancer       Date:  1996-03-28       Impact factor: 7.396

Review 9.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

10.  Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes.

Authors:  F Sallusto; D Lenig; C R Mackay; A Lanzavecchia
Journal:  J Exp Med       Date:  1998-03-16       Impact factor: 14.307

View more
  81 in total

Review 1.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

2.  A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.

Authors:  Todd A Fehniger; Sarah Larson; Kathryn Trinkaus; Marilyn J Siegel; Amanda F Cashen; Kristie A Blum; Timothy S Fenske; David D Hurd; Andre Goy; Stephanie E Schneider; Catherine R Keppel; Nina D Wagner-Johnston; Kenneth R Carson; Nancy L Bartlett
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

3.  High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.

Authors:  R Rust; G Harms; T Blokzijl; M Boot; A Diepstra; J Kluiver; L Visser; S-C Peh; M Lim; W A Kamps; S Poppema; A van den Berg
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

Review 4.  Adoptive immunotherapy for Hodgkin's lymphoma.

Authors:  Alana A Kennedy-Nasser; Catherine M Bollard; Cliona M Rooney
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

5.  Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma.

Authors:  Christoph Renné; Jose Ignacio Martin-Subero; Maren Eickernjäger; Martin-Leo Hansmann; Ralf Küppers; Reiner Siebert; Andreas Bräuninger
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 6.  Immunotherapies for Hodgkin's lymphoma.

Authors:  Yvette L Kasamon; Richard F Ambinder
Journal:  Crit Rev Oncol Hematol       Date:  2007-11-19       Impact factor: 6.312

Review 7.  Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Authors:  Catherine S Diefenbach; Joseph M Connors; Jonathan W Friedberg; John P Leonard; Brad S Kahl; Richard F Little; Lawrence Baizer; Andrew M Evens; Richard T Hoppe; Kara M Kelly; Daniel O Persky; Anas Younes; Lale Kostakaglu; Nancy L Bartlett
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

Review 8.  Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Authors:  Catherine Diefenbach; Ranjana Advani
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

Review 9.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

10.  Epstein-Barr virus-associated anaplastic large cell variant of diffuse large B-cell-type non-Hodgkin's lymphoma with concurrent p53 protein expression.

Authors:  Yuko Hirose; Yasufumi Masaki; Kumiko Shimoyama; Toshihiro Fukushima; Hiroshi Kawabata; Noriyoshi Ogawa; Yuji Wano; Susumu Sugai
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.